Literature DB >> 18029522

Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. Epidural analgesia/anaesthesia versus systemic intravenous opioid analgesia in the management of blunt thoracic trauma.

Richard Parris1.   

Abstract

A short cut review was carried out to establish whether an epidural infusion provided any advantage over intravenous analgesia in the management of blunt thoracic trauma. Only four papers presented evidence to answer the clinical question. The author, date and country of publication, patient group studied, study type, relevant outcomes, results and study weaknesses of this paper are presented in table 2. The clinical bottom line is that epidural analgesia may provide better pain relief, but may not alter clinical outcomes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18029522      PMCID: PMC2658360          DOI: 10.1136/emj.2007.054999

Source DB:  PubMed          Journal:  Emerg Med J        ISSN: 1472-0205            Impact factor:   2.740


  4 in total

1.  The treatment of patients with multiple rib fractures using continuous thoracic epidural narcotic infusion.

Authors:  D A Ullman; J B Fortune; B B Greenhouse; R E Wimpy; T M Kennedy
Journal:  Reg Anesth       Date:  1989 Jan-Feb

2.  Prospective, randomized comparison of epidural versus parenteral opioid analgesia in thoracic trauma.

Authors:  M R Moon; F A Luchette; S W Gibson; J Crews; G Sudarshan; J M Hurst; K Davis; J A Johannigman; S B Frame; J E Fischer
Journal:  Ann Surg       Date:  1999-05       Impact factor: 12.969

3.  Prospective evaluation of epidural and intravenous administration of fentanyl for pain control and restoration of ventilatory function following multiple rib fractures.

Authors:  R C Mackersie; T G Karagianes; D B Hoyt; J W Davis
Journal:  J Trauma       Date:  1991-04

4.  Epidural analgesia improves outcome after multiple rib fractures.

Authors:  Eileen M Bulger; Thomas Edwards; Patricia Klotz; Gregory J Jurkovich
Journal:  Surgery       Date:  2004-08       Impact factor: 3.982

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.